相关实验视频

Updated: Jan 13, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

AMT-130基因疗法:对亨廷顿病的一种有希望的疾病修饰方法

Chisanga Mwape¹, Afnan Ahmad Qureshi², Muhammad Zaid Saeed²

¹Department of Internal Medicine, The Copperbelt University School of Medicine, Ndola, Zambia.

Annals of medicine and surgery (2012)

|January 7, 2026

概括

AMT-130基因疗法通过减少突变的亨廷顿蛋白来为亨廷顿病 (HD) 提供一种新的方法. 早期的临床数据表明,有可能减缓疾病的进展,超越症状治疗.

科学领域:

神经科学是一个神经科学.
遗传学遗传学是一个
药理学药理学是指药理学的学科.

背景情况:

亨廷顿病 (HD) 是一种进展性神经退行性疾病,由亨廷丁 (HTT) 基因中扩大CAG重复引起.
目前对HD的治疗主要是症状性,缺乏疾病修饰疗法.
突变的亨廷丁蛋白积累导致神经元功能障碍和HD中的损失.

研究的目的:

为了评估AMT-130,一种针对亨廷顿病的新型基因疗法.
通过微RNA输送来评估向突变狩猎丁蛋白 (mHTT) 的安全性和有效性.
探索AMT-130在修改HD进展方面的潜力.

主要方法:

AMT-130利用一种腺相关病毒血清型5 (AAV5) 载体来输送工程微RNA (miHTT).
治疗包括对尾骨和骨进行立体性脑内输液.
使用临床前模型和早期临床试验来评估安全性和有效性.

主要成果:

临床前研究表明,广泛的载体分布,长期表达,以及降低的亨廷丁水平.
在动物模型中,AMT-130证明了运动性能和生存率的改善.
早期的临床数据表明,它具有良好的安全性,降低了神经纤维光链水平,并稳定了运动衰退.

结论:

AMT-130证明了作为亨廷顿病的疾病修饰疗法的潜力.
基因疗法在减少突变的亨廷丁蛋白和减缓疾病进展方面表现有前途.
AMT-130可能代表着HD治疗的范式转变,并激发其他神经退行性疾病的治疗方法.

关键词:

在 AMT-130 中,它是 AMT-130 的.亨廷顿病就是亨廷顿病.基因治疗的基因疗法这是一个微型RNA.神经退行症的神经退行症

更多相关视频

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...